Search peptides, terms, sources/
Melanocortin

Setmelanotide

Synthetic peptide that activates the MC4 receptor, studied in rare forms of obesity. UK prescription-only medicine for three rare conditions; trials were small and do not cover common obesity.

UK status and evidence last reviewed .

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Moderate evidence (level 3 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the medicine.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

UK status
Licensed UK medicineChecked
Best study type
Human trials4 human trials

What is Setmelanotide?

Setmelanotide is a synthetic peptide that selectively activates the melanocortin-4 receptor, which helps regulate hunger and energy use. In the UK it is a licensed prescription-only medicine for obesity and hunger control in three rare conditions, not common obesity, and the trials behind it are small, the largest randomised one having 120 people.

The three conditions are acquired hypothalamic obesity, Bardet-Biedl syndrome, and genetically confirmed POMC (including PCSK1) or LEPR deficiency.

Class
Synthetic cyclic melanocortin-receptor agonist (MC4R-selective)
Origin
Analogue / modified
Research areas
Weight Management
UK status
Licensed UK medicine
Best study type
Human trials
Evidence last reviewed

How does Setmelanotide work?

According to the UK product information, setmelanotide switches on MC4 receptors in the brain, which regulate hunger, fullness and energy use. In rare diseases where this pathway is not activated enough, it is believed to restore pathway activity and so reduce hunger. Its weaker action on the MC1 receptor is linked to the skin darkening reported with the drug.

The mechanism in more detail

Setmelanotide is a selective agonist of the melanocortin-4 receptor (MC4R). According to the UK product information, MC4 receptors in the brain regulate hunger, satiety and energy expenditure. In diseases where this pathway is not activated enough, setmelanotide is believed to restore pathway activity, which reduces hunger and promotes weight loss.

The product information also states that setmelanotide has weaker activity at the MC1 receptor, and that this accounts for the skin darkening reported with the drug. A 2026 review describes this MC1R effect as a bystander effect, as opposed to afamelanotide, which targets MC1R directly.

The conditions it is licensed for involve disrupted signalling upstream of MC4R (POMC, PCSK1 or LEPR deficiency; Bardet-Biedl syndrome; damage to the hypothalamus). The trial evidence below is from these groups only and does not show a benefit in people with common obesity.

Classification and structure

Names
Setmelanotide; Imcivree (UK brand name)
Class
Synthetic cyclic melanocortin-receptor agonist (MC4R-selective)
Origin
Analogue / modified
Structure
Synthetic peptide agonist of the melanocortin-4 receptor. The UK product information describes it as a selective MC4 receptor agonist with weaker activity at the MC1 receptor.
Routes used in the research
Subcutaneous injection in the trials and the licensed product.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

Setmelanotide has 5 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

5 findings

Counts recorded findings by grade. It does not rate the medicine.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
03101

POMC and LEPR deficiency trials Limited

Two single-arm, open-label phase 3 trials enrolled 10 people with POMC deficiency and 11 with LEPR deficiency. At about one year, 8 of 10 (80%) and 5 of 11 (45%) had lost at least 10% of body weight, and the hunger score fell by about 27% (POMC) and 44% (LEPR) in the 7 people per trial whose hunger scores were analysed. No serious treatment-related adverse events were reported. Injection-site reactions occurred in all participants, and all 10 people with POMC deficiency had skin pigmentation changes.

Study type
Human trial
Population
10 people with POMC deficiency and 11 with LEPR deficiency; 10 hospitals; single-arm, open-label phase 3.
Source
1 Clement et al., 2020

Limitation: Two very small trials with no control group, in ultra-rare conditions.

Limitations in full

Two very small trials with no control group, in ultra-rare conditions. The hunger result covers only 7 people per trial. Results come from open-label use, so people knew they were on treatment.

Bardet-Biedl and Alstrom syndromes Limited

In a randomised, double-blind, placebo-controlled phase 3 trial with an open-label period, 38 people with Bardet-Biedl or Alstrom syndrome (19 per arm) were studied. Among people with Bardet-Biedl syndrome aged 12 and over, 32.3% reached at least 10% weight reduction (95% CI 16.7 to 51.4; P = 0.0006).

Study type
Human trial
Population
38 people with Bardet-Biedl or Alstrom syndrome; 19 per arm, setmelanotide or placebo.
Source
2 Haqq et al., 2022

Limitation: Small trial in rare conditions.

Limitations in full

Small trial in rare conditions. The abstract record read does not state the comparator-arm rate. Evidence for Alstrom syndrome alone is limited by small numbers.

Acquired hypothalamic obesity Moderate

In a 52-week phase 3 randomised trial of 120 people with acquired hypothalamic obesity (81 on setmelanotide, 39 on placebo), body mass index fell by 16.5% on average with setmelanotide and rose by 3.3% with placebo (P under 0.001). The weekly average of maximal daily hunger scores fell by 2.73 points versus 1.45 points (P = 0.009). Serious adverse events occurred in 28% on setmelanotide versus 8% on placebo.

Study type
Human trial
Population
120 people with acquired hypothalamic obesity, mean age 19.9 (range 4 to 66); 2:1 randomisation.
Source
3 Miller et al., 2026

Limitation: Single trial of 52 weeks in a mixed-age group, so results may not apply equally to children and adults.

Limitations in full

Single trial of 52 weeks in a mixed-age group, so results may not apply equally to children and adults. Serious adverse events were more frequent on setmelanotide.

Bardet-Biedl syndrome versus a registry comparison group Limited

When 29 Bardet-Biedl trial participants treated for 52 weeks were compared with 58 matched people from a registry, 58.6% of the treated group met the primary weight endpoint versus 6.9% of the registry group (P under 0.001). In children and adolescents the figures were 71.4% versus 10.7%, and in adults 46.7% versus 3.3%.

Study type
Human trial
Population
29 treated Bardet-Biedl trial participants and 58 matched registry controls.
Source
4 Argente et al., 2026

Limitation: The comparison group came from a registry, not from randomisation, so unmeasured differences may remain.

Limitations in full

The comparison group came from a registry, not from randomisation, so unmeasured differences may remain. The exact definition of the primary endpoint was not read from the abstract record.

Licensed indications and mechanism Not graded

The UK product information lists three indications: acquired hypothalamic obesity (adults and children aged 4 and over), Bardet-Biedl syndrome (adults and children aged 2 and over), and genetically confirmed biallelic POMC (including PCSK1) or LEPR deficiency (adults and children aged 2 and over). It describes setmelanotide as a selective MC4 receptor agonist with weaker activity at the MC1 receptor.

Study type
Regulatory-clinical source
Population
Not applicable; regulator-approved product information.
Source
5 Rhythm Pharmaceutical UK Ltd (company listed on eMC), 2026

Limitation: A manufacturer-authored, regulator-approved summary, not an independent analysis.

What safety findings have been reported?

3 safety findings are recorded for Setmelanotide. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Skin pigmentation and moles

The UK product information warns that generalised skin darkening and darkening of existing moles (naevi) may occur, and recommends full-body skin examinations every year. Hyperpigmentation disorders were the most common adverse reaction (66%), followed by injection-site reactions (45%), nausea (36%) and headache (19%); vomiting was reported in 17%.

Source
5 Rhythm Pharmaceutical UK Ltd (company listed on eMC), 2026

Depression and sexual adverse reactions

The UK product information states that depression has been reported and that discontinuation should be considered if suicidal thoughts or behaviours occur. Spontaneous penile erections have been reported, and an erection lasting more than 4 hours needs emergency care because of the risk of priapism. Heart rate and blood pressure should be monitored at least every 6 months.

Source
5 Rhythm Pharmaceutical UK Ltd (company listed on eMC), 2026

Serious adverse events in the hypothalamic obesity trial

In the 52-week hypothalamic obesity trial, adverse events occurred in 100% of the setmelanotide group and 90% of the placebo group, and serious adverse events in 28% versus 8%. The most common events with setmelanotide were skin hyperpigmentation, nausea, vomiting and headache.

Source
3 Miller et al., 2026

What is Setmelanotide's UK regulatory status?

Marketing authorisation
Licensed in the UK. The electronic Medicines Compendium lists Imcivree solution for injection, with Rhythm Pharmaceutical UK Ltd named as the company.
Prescription status
Prescription-only medicine (POM).
Medicine class
Licensed medicinal product.
MHRA position
Setmelanotide appears on the MHRA Products database active-substance index (checked 14 November 2026). The eMC product record was last updated on 18 August 2026.
Authorised use
Treatment of obesity and control of hunger in three groups: adults and children aged 4 and over with acquired hypothalamic obesity due to hypothalamic injury or impairment; adults and children aged 2 and over with genetically confirmed Bardet-Biedl syndrome; and adults and children aged 2 and over with genetically confirmed loss-of-function biallelic POMC (including PCSK1) deficiency or biallelic LEPR deficiency. Not licensed for common obesity.
Other restrictions
NHS funding decisions are separate from the marketing authorisation.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations, and none of them means a product is safe to obtain or use.

References

5 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Clement K, van den Akker E, Argente J, et al.; Setmelanotide POMC and LEPR Phase 3 Trial Investigators (2020). Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. The Lancet Diabetes & EndocrinologyHuman clinical trial · DOI 10.1016/S2213-8587(20)30364-8 · PMID 33137293 · Original ↗
  2. Haqq AM, Chung WK, Dollfus H, et al. (2022). Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. The Lancet Diabetes & EndocrinologyHuman clinical trial, RCT · DOI 10.1016/S2213-8587(22)00277-7 · PMID 36356613 · Original ↗
  3. Miller JL, van Santen HM, Phillips SA, et al.; TRANSCEND Trial Group (2026). Setmelanotide for the Treatment of Acquired Hypothalamic Obesity. New England Journal of MedicineHuman clinical trial, RCT · DOI 10.1056/NEJMoa2512275 · PMID 42418774 · Original ↗
  4. Argente J, Haqq AM, Schorfheide JL, et al.; Phase 3 BBS Trial Investigators (2026). Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort. Obesity (Silver Spring)Human clinical trial, Human observational · DOI 10.1002/oby.70125 · PMID 41703984 · Original ↗
  5. Rhythm Pharmaceutical UK Ltd (company listed on eMC) (2026). Imcivree solution for injection (setmelanotide): Summary of Product Characteristics. electronic Medicines Compendium (eMC) · Original ↗

Questions about Setmelanotide

What is Setmelanotide?

Setmelanotide is a synthetic peptide that selectively activates the melanocortin-4 receptor, which helps regulate hunger and energy use. In the UK it is a licensed prescription-only medicine for obesity and hunger control in three rare conditions, not common obesity, and the trials behind it are small, the largest randomised one having 120 people. Read what it is.

Is Setmelanotide licensed in the UK?

PeptGuru records Setmelanotide's UK status as: Licensed UK medicine. The licensed products and their approved uses are listed in the UK status section. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on Setmelanotide show?

PeptGuru records 5 research findings for Setmelanotide: 4 from human trials and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for Setmelanotide?

3 safety findings are recorded, including: skin pigmentation and moles; depression and sexual adverse reactions; serious adverse events in the hypothalamic obesity trial. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for Setmelanotide?

All 5 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · Setmelanotide added: 5 findings and 3 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • CagrilintideAM833

    Not licensed in the UK. Investigational long-acting amylin analogue studied for weight management, alone and with semaglutide.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Liraglutide

    Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateLicensed UK medicine
  • RetatrutideLY3437943

    Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.

    Metabolic and incretinHuman trialsEvidence reviewed
    ModerateNot licensed in the UK
  • Semaglutide

    GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.

    Metabolic and incretinHuman trialsEvidence reviewed
    StrongLicensed UK medicine

Compare Setmelanotide with Cagrilintide

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.